Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $141.10 | Total: $705.50 |
| 1 | 10 | $119.52 | Total: $1,195.20 |
| 1 | 25 | $101.26 | Total: $2,531.50 |
| 1 | 50 | $86.32 | Total: $4,316.00 |
| 1 | 100 | $74.70 | Total: $7,470.00 |
Overview
CP 461 (UNII-68OJX9I7DT), a specific PDE2A inhibitor, is a novel pro-apoptotic compound that inhibits cyclic GMP phosphodiesterase but not cyclooxygenase-1 or -2. CP 461 inhibits the growth of a variety of human tumor cell lines in vitro and selectively induces apoptosis in cancer cell lines, but not in normal cells.
Chemical Properties
| Molecular Formula | C25H22ClFN2O |
| Molecular Weight | 420.91 |
| CAS Numbers | 227619-96-7 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C(C(NCC1=CC=CC=C1)=O)C=2C=3C(C(=CC=4C=CN=CC4)C2C)=CC=C(F)C3.Cl |
Storage and Handling
0C Short Term, -20C Long Term
References
Sun W, et al. Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer. Clin Cancer Res. 2002 Oct;8[10] 3100-4.